ARSA and metachromatic leukodystrophy: In the ARSA−/− mouse model of metachromatic leukodystrophy (MLD), treatment with AAV-ARSA gene therapy significantly elevates ARSA enzymatic activity in the brain and reduces systemic sulfatide accumulation [48].